Exploring allelic imbalance within paraffin-embedded tumor biopsies using pyrosequencing technology

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 9, 2006, Pages 1076-1081

  Pascual, Manuel Hidalgo ^a   Royo, José Luis ^b   Martínez Tello, Francisco Jose ^a   Crespo, Carmen ^c   Salinas, Ana ^b   Herrero, Eduardo Ferrero ^a   Lopez García, María ^c   Real, Luis Miguel ^b   Ruiz, Agustín ^b   Ramirez Lorca, Reposo ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

11q13; Allelic imbalance; EMSY; PAK1; Pyrosequencing

Indexed keywords

PARAFFIN;

ALLELE; ARTICLE; AUTOMATION; BREAST CANCER; CONTROLLED STUDY; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; MOLECULAR GENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID CANCER; TUMOR BIOPSY;

ALLELIC IMBALANCE; AUTOMATION; BASE SEQUENCE; BIOPSY; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 11; HETEROZYGOTE; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; PARAFFIN EMBEDDING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; REPRESSOR PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 33748524570     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.198     Document Type: Article

References (21)

1. Kinzler KW, Vogelstein B. The genetic basis of human cancer, 2nd ed. Toronto: McGraw-Hill, 2002.
2. Onyango P. Genomics and cancer. Curr Opin Oncol 2002;14:79-85.
3. Shih IM, Wang TL. Apply innovative technologies to explore cancer genome. Curr Opin Oncol 2004;17:33-8.
4. Zhou X, Li C, Mok S, Chen Z, Wong DT. Whole genome loss of heterozygosity profiling on oral squamous cell carcinoma by high-density single nucleotide polymorphic allele (SNP) array. Cancer Genet Cytogenet 2004;151:82-4.
5. Kennedy GC, Matsuzaki H, Dong S, Liu WM, Huang J, Liu G, et al. Large-scale genotyping of complex DNA. Nat Biotechnol 2003;21:1233-7.
6. Zhou X, Rao NP, Cole SW, Mok SC, Chen Z, Wong DT. Progress in concurrent analysis of loss of heterozygosity and comparative genomic hybridization utilizing high density single nucleotide polymorphism arrays. Cancer Genet Cytogenet 2005;159:53-7.
7. Zhou X, Mok SC, Chen Z, Li Y, Wong DT. Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array. Hum Genet 2004;115:327-30.
8. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphatase. Science 1998;281:363-5.
9. Ahmadian A, Gharizadeh B, Gustafsson AC, Sterky F, Nyren P, Uhlen M, et al. Single-nucleotide polymorphism analysis by pyrosequencing. Anal Biochem 2000;280:103-10.
10. Van Goethem G, Dermaut B, Löfgren A, Martin JJ, Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001;28:211-2.
11. Ahmadian A, Lundeberg J, Nyren P, Uhlen M, Ronaghi M. Analysis of the p53 tumor suppressor gene by pyrosequencing. Biotechniques 2000;28:140-7.
12. Garcia CA, Ahmadian A, Gharizadeh B, Lundeberg J, Ronaghi M, Nyren P. Mutation detection by pyrosequencing: sequencing of exons 5-8 of the p53 tumor suppressor gene. Gene 2000;253:249-57.
13. Bekri S, Adelaide J, Merscher S, Grosgeorge J, CaroliBosc F, Perucca-Lostanlen D, et al. Detailed map of a region commonly amplified at 11q13→q14 in human breast carcinoma. Cytogenet Cell Genet 1997;79:125-31.
14. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003;115:523-35.
15. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 2003;163:985-92.
16. Simon R, Nocito A, Hübscher T, Bucher C, Torhorst J, Schraml P, et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141-6.
17. Manes S, Mira E, Colomer R, Montero S, Real LM, Gomez-Mouton C, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003;198:1381-9.
18. Rodriguez C, Hughes-Davies L, Valles H, Orsetti B, Cuny M, et al. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res 2004;10:5785-91.
19. King MC. A novel BRCA2-binding protein and breast and ovarian tumorigenesis. N Engl J Med 2004;350:1252-3.
20. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992;258:818-21.
21. Ylstra B, van den Ijssel P, Carvalho B, Brakenhoff RH, Meijer GA. BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Res 2006;34:445-50.